Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Royal Caribbean Cruises Ltd — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.08 (market cap $8.04B), while Royal Caribbean Cruises Ltd trades at $292.37 (market cap $75.92B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 9.4× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Royal Caribbean Cruises Ltd pays a 1.77% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | RCL | |
|---|---|---|
Market Cap | $8.04B | $75.92B |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $365.84 |
52-Week Low | $241.71 | $246.71 |
Enterprise Value | $7.85B | $97.20B |
Dividend Yield | — | 1.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Royal Caribbean (RCL) trades at $288.61, up 1.14% today, with a bullish technical setup near key resistance at $292. The company demonstrates strong fundamental momentum, with 2025 revenue reaching $17.93 billion and net income surging to $4.27 billion, yielding a robust 24.36% net margin. Analyst consensus is positive, with a $328 price target implying 14% upside, supported by 25 buy ratings. Recent news highlights Caribbean demand strength offsetting European softness, with Q2 2026 earnings due July 28.
RCL's outlook is favorable, driven by earnings beats, expanding margins, and strategic destination investments. Key risks include Europe demand volatility, high debt levels, and competitive pressures. Institutional sentiment leans bullish, but macroeconomic sensitivity and execution on yield growth remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
